Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In neuronal cultures, the expression of genes either relevant to SCZ risk (<i>Drd2, Gatad2a</i>, <i>Slc28a1</i>, <i>Cnr1</i>) or indexing co-expression in our module (<i>Btg4</i>, <i>Chit1</i>, <i>Osr1</i>, <i>Gpld1</i>) was significantly modified by gain and loss of Nurr1 and Err1.
|
31811028 |
2020 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with dopamine D2 receptor antagonism that is exhibited by most antipsychotics, partial agonism may result in improved outcomes in major depressive disorder and in schizophrenia.
|
31406978 |
2019 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 7 gene polymorphisms from DRD2 (rs1800497, rs1079597, rs1800498, rs1801028) and 5-HT2 A (rs6313, rs6311, rs6305) were genotyped for their association with schizophrenia.
|
30389402 |
2019 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cortical D2 dopamine receptor (Drd2) have mostly been examined in the context of cognitive function regulation and neurotransmission modulation of medial prefrontal cortex by principal neurons and parvalbumin positive, fast-spiking, interneurons in schizophrenia.
|
30295716 |
2019 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The study aimed to confirm the association of the schizophrenia genome-wide association study (GWAS) hit rs2514218 located near the DRD2 gene with the risk of the disease and to investigate the relationships between rs2514218 and schizophrenia-related clinical and neuroimaging phenotypes.
|
31054090 |
2019 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The -141C Ins/Del polymorphism in DRD2 (rs1799732) is functional and associated with SCZ.
|
31176829 |
2019 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After Bonferroni correction, there was no association found between DRD2 gene promoter region with schizophrenia risk in the northern Chinese Han population.
|
30657260 |
2019 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings underscore the need for a reexamination of cortical DRD2 mediated synaptic plasticity in the context of schizophrenia and other psychotic disorders.
|
30528973 |
2019 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The D2 dopamine receptor (Drd2) is implicated in several brain disorders such as schizophrenia, Parkinson's disease, and drug addiction.
|
30604007 |
2019 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the clinical efficacy of dopamine D2 receptor antagonists against positive symptoms of schizophrenia supports the dopamine hypothesis of the disease, the resistance of negative and cognitive symptoms to these drugs implicates other systems in its pathophysiology.
|
31291870 |
2019 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.
|
30332506 |
2019 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For example, an elegant roadmap was laid out a year ago by Karolina Kauppi and colleagues wherein they combined a data set for schizophrenia risk genes and another set of genes associated with antipsychotic drug targets.<sup>3</sup> Using this "network biology" approach, they identified four schizophrenia risk genes that were also antipsychotic drug targets (GRM3, DRD2, CHRM4, and CYP2D6); they also found several molecular targets that are not currently connected to antipsychotic drug treatment, providing researchers with some potential targets for novel therapeutics.<sup>4</sup>.
|
31340894 |
2019 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
PET imaging of dopamine-D2 receptor internalization in schizophrenia.
|
28507321 |
2018 |
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In a cohort of schizophrenia inpatients CYP2D6 metabolic activity affects mean AP daily dose only in the presence of DRD2 Taq1A polymorphic allele.
|
29930225 |
2018 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
NQ treatment in rats increases dopamine D2 receptor sensitivity throughout the animal's lifetime, consistent with schizophrenia.
|
29444518 |
2018 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Effects of the -141C insertion/deletion polymorphism in the dopamine D2 receptor gene on the dopamine system in the striatum in patients with schizophrenia.
|
29627696 |
2018 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, we investigated in HC association of LPFC-amygdala effective connectivity with a genome-wide supported variant increasing genetic risk for SCZ and possibly relevant to emotion processing (DRD2 rs2514218).
|
28981847 |
2018 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The dopaminergic hypothesis of schizophrenia (SZ) postulates that positive symptoms of SZ, in particular psychosis, are due to disturbed neurotransmission via the dopamine (DA) receptor D2 (DRD2).
|
30546022 |
2018 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Human genetic studies also show a significant association of DRD2 polymorphisms with disorders including schizophrenia and Parkinson's disease.
|
29107444 |
2017 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association between SLC6A2, SLC6A3, DRD2 polymorphisms and schizophrenia in the Han Chinese population.
|
28454051 |
2017 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antipsychotic drugs, all of which block the dopamine D2 receptor to a greater or lesser extent, are the mainstay for the pharmacological treatment of schizophrenia.
|
27756689 |
2017 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DRD2 C957T is also associated with schizophrenia, with the C allele being the risk allele.
|
29945153 |
2017 |
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of the current exploratory study was to examine the interaction of dopaminergic genes (coding for dopamine receptor D2, DRD2, and for Catecholamine-O-Methyl-Transferase, COMT) with the diagnostic of schizophrenia in (i) the executive control of attention, (ii) selective attention, and (iii) executive functions.
|
28085950 |
2017 |
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Dopamine receptor D2 short, vesicular monoamine transporter (VMAT2) and DAT mRNAs were significantly decreased in schizophrenia, with no change in DRD3 mRNA, DRD3nf mRNA and DAT protein between diagnostic groups.
|
28094812 |
2017 |
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A regulatory dopamine 2-receptor gene (DRD2) polymorphism (rs1076560; G>T) has been identified as a genetic risk factor for schizophrenia.
|
28104410 |
2017 |